Roche’ Cobas HPV Test Receives FDA Approval for First-line Cervical Cancer Screening

12:03 EDT 2 Aug 2018 | Speciality Pharma Journal

TUCSON, Ariz., July 30, 2018 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received U.S. Food and Drug Administration (FDA) approval for the cobas® HPV Test to be used as the first-line screening test for cervical cancer in women 25 and older using cervical specimens collected in SurePath preservative fluid, …

Roche’ Cobas HPV Test Receives FDA Approval for First-line Cervical Cancer Screening

More From BioPortfolio on "Roche’ Cobas HPV Test Receives FDA Approval for First-line Cervical Cancer Screening"